TY - JOUR
T1 - p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up
T2 - An Observational Study
AU - Fabi, Alessandra
AU - Mottolese, Marcella
AU - Di Benedetto, Anna
AU - Sperati, Francesca
AU - Ercolani, Cristiana
AU - Buglioni, Simonetta
AU - Nisticò, Cecilia
AU - Ferretti, Gianluigi
AU - Vici, Patrizia
AU - Perracchio, Letizia
AU - Malaguti, Paola
AU - Russillo, Michelangelo
AU - Botti, Claudio
AU - Pescarmona, Edoardo
AU - Cognetti, Francesco
AU - Terrenato, Irene
N1 - Funding Information:
Editorial assistance was provided by Luca Giacomelli, PhD, Ambra Corti, and Aashni Shah (Polistudium SRL). This assistance was supported by internal funds.
Publisher Copyright:
© 2020 Elsevier Inc.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/12
Y1 - 2020/12
N2 - Introduction: p53 and antiapoptotic B-cell leukemia/lymphoma 2 (BLC2) have been proposed as prognostic markers for early breast cancer (BC), although their relationship with conventional parameters and patient prognosis, as well as their distribution within the molecular BC subtypes remains uncertain. Patients and Methods: In this observational study, we analyzed the immunohistochemical expression of p53 and BLC2 in 1099 early BC patients surgically treated between 2000 and 2006 and followed for at least 5 years, also considering their association with pathologic factors and molecular subtypes, as well as their influence on disease-free survival. Results: p53 and BLC2 are distributed differently across molecular subtypes (P < .0001); in particular, p53 positivity and BLC2 negativity seems to be associated with more aggressive conventional tumor phenotypes. Moreover, BLC2 negativity seems to be a significant discriminating factor for disease-free survival (P = .003) according to Kaplan-Meier analysis, while p53 seems to have no discriminating effect. Among patients with discordant p53/BLC2 phenotype, the combination p53+BLC2− seems to be associated with the worst outcomes (P = .007) and significantly influenced the clinical course of node-negative patients treated only with hormone therapy (P = .004). Conclusion: These two biomarkers, in addition to conventional pathologic factors and molecular subtype, could help define the risk and outcome of BC. Management of early breast cancer (BC) is complicated by the limited number of clinicopathologic prognostic factors available. We analyzed p53 and antiapoptotic B-cell leukemia/lymphoma 2 (BLC2) immunohistochemistry expression in 1099 early BC patients. p53 and BLC2 are distributed differently across BC molecular subtypes; p53-positive/BLC2-negative BC corresponds to more aggressive phenotypes. p53 and BLC2 could help define the risk and outcome of BC in addition to molecular subtypes.
AB - Introduction: p53 and antiapoptotic B-cell leukemia/lymphoma 2 (BLC2) have been proposed as prognostic markers for early breast cancer (BC), although their relationship with conventional parameters and patient prognosis, as well as their distribution within the molecular BC subtypes remains uncertain. Patients and Methods: In this observational study, we analyzed the immunohistochemical expression of p53 and BLC2 in 1099 early BC patients surgically treated between 2000 and 2006 and followed for at least 5 years, also considering their association with pathologic factors and molecular subtypes, as well as their influence on disease-free survival. Results: p53 and BLC2 are distributed differently across molecular subtypes (P < .0001); in particular, p53 positivity and BLC2 negativity seems to be associated with more aggressive conventional tumor phenotypes. Moreover, BLC2 negativity seems to be a significant discriminating factor for disease-free survival (P = .003) according to Kaplan-Meier analysis, while p53 seems to have no discriminating effect. Among patients with discordant p53/BLC2 phenotype, the combination p53+BLC2− seems to be associated with the worst outcomes (P = .007) and significantly influenced the clinical course of node-negative patients treated only with hormone therapy (P = .004). Conclusion: These two biomarkers, in addition to conventional pathologic factors and molecular subtype, could help define the risk and outcome of BC. Management of early breast cancer (BC) is complicated by the limited number of clinicopathologic prognostic factors available. We analyzed p53 and antiapoptotic B-cell leukemia/lymphoma 2 (BLC2) immunohistochemistry expression in 1099 early BC patients. p53 and BLC2 are distributed differently across BC molecular subtypes; p53-positive/BLC2-negative BC corresponds to more aggressive phenotypes. p53 and BLC2 could help define the risk and outcome of BC in addition to molecular subtypes.
KW - Immunohistochemistry
KW - Individualized medicine
KW - Prognosis
KW - Prognostic factors
KW - TP53
UR - http://www.scopus.com/inward/record.url?scp=85086731780&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086731780&partnerID=8YFLogxK
U2 - 10.1016/j.clbc.2020.05.005
DO - 10.1016/j.clbc.2020.05.005
M3 - Article
C2 - 32580907
AN - SCOPUS:85086731780
VL - 20
SP - e761-e770
JO - Clinical Breast Cancer
JF - Clinical Breast Cancer
SN - 1526-8209
IS - 6
ER -